BioNTech Investor Day Presentation Deck

iNeST | Autogene cevumeran (BNT122) Functional T cells confirmed by ELISPOT in immune responders Number of neoantigens in autogene cevumeran 20- 15- 10- 0 Assay 2: T cell specificity to autogene cevumeran neoantigens by IFNY ELISPOT Responders (n=8) iNeST is being developed in collaboration with Genentech. Balachandran VP, et al. ASCO Annual Meeting 2022; Poster presentation 2516. Non-responders (n=8) Immunogenic Non-immunogenic No data IFNy spots x 10° cells 1000 100 10 0 Responders (n=8) NUM 20 40 60 80 Weeks after surgery *Patient treated in non-protocol-specified sequence mRNA cancer vaccines 100 BIONTECH 105

View entire presentation